HUP0101139A3 - Transdermal delivery of particulate vaccine compositions - Google Patents

Transdermal delivery of particulate vaccine compositions

Info

Publication number
HUP0101139A3
HUP0101139A3 HU0101139A HUP0101139A HUP0101139A3 HU P0101139 A3 HUP0101139 A3 HU P0101139A3 HU 0101139 A HU0101139 A HU 0101139A HU P0101139 A HUP0101139 A HU P0101139A HU P0101139 A3 HUP0101139 A3 HU P0101139A3
Authority
HU
Hungary
Prior art keywords
transdermal delivery
vaccine compositions
particulate vaccine
particulate
compositions
Prior art date
Application number
HU0101139A
Other languages
Hungarian (hu)
Original Assignee
Powderject Vaccines Inc Madiso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc Madiso filed Critical Powderject Vaccines Inc Madiso
Publication of HUP0101139A2 publication Critical patent/HUP0101139A2/en
Publication of HUP0101139A3 publication Critical patent/HUP0101139A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HU0101139A 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions HUP0101139A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6714697P 1997-12-02 1997-12-02
US8268698P 1998-04-22 1998-04-22
PCT/US1998/025563 WO1999027961A1 (en) 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions

Publications (2)

Publication Number Publication Date
HUP0101139A2 HUP0101139A2 (en) 2001-07-30
HUP0101139A3 true HUP0101139A3 (en) 2003-11-28

Family

ID=26747529

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101139A HUP0101139A3 (en) 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions

Country Status (9)

Country Link
EP (1) EP1035867A1 (en)
JP (1) JP2001524533A (en)
CN (1) CN1285753A (en)
AU (1) AU756828B2 (en)
CA (1) CA2312900A1 (en)
HU (1) HUP0101139A3 (en)
IL (1) IL136488A0 (en)
NZ (1) NZ504894A (en)
WO (1) WO1999027961A1 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
WO2001000232A2 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CA2387326A1 (en) 1999-10-11 2001-04-19 Needleless Ventures, Inc. Universal anti-infectious protector for needleless injectors
EP1913957B1 (en) * 1999-11-03 2010-03-17 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
EP1227840B1 (en) * 1999-11-03 2007-10-03 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU784781B2 (en) * 1999-11-10 2006-06-15 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
EP1289494A2 (en) * 2000-06-08 2003-03-12 Powderject Vaccines, Inc. Powder compositions
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ES2392943T3 (en) 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Anti-tumor vaccines
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
DK1944318T3 (en) 2003-07-21 2011-06-14 Transgene Sa Multifunctional cytokines
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2580103C (en) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Immunogenic composition
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514841A (en) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Influenza vaccine comprising a combination of particulate adjuvant and immunopotentiator
DK1951300T3 (en) * 2005-11-04 2011-10-03 Novartis Vaccines & Diagnostic Change of Th1 / Th2 balance in split flu vaccines with adjuvants
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP5579387B2 (en) 2005-12-22 2014-08-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine containing Streptococcus pneumoniae capsular polysaccharide conjugate
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX337528B (en) 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Immunogenic composition.
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
MX2009003325A (en) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vaccine comprising an oil in water emulsion adjuvant.
SI2086582T1 (en) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JP5653215B2 (en) 2007-09-12 2015-01-14 ノバルティス アーゲー GAS57 mutant antigen and GAS57 antibody
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101977926B (en) 2007-12-21 2014-10-08 诺华股份有限公司 Mutant forms of streptolysin O
EP2271360B1 (en) 2008-04-16 2015-09-23 GlaxoSmithKline Biologicals S.A. Vaccine
AU2009296458A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
MX2011007456A (en) 2009-01-12 2011-08-03 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria.
CN102307590A (en) 2009-02-10 2012-01-04 诺华有限公司 Influenza vaccines with reduced amounts of squalene
CN102438650A (en) 2009-03-06 2012-05-02 诺华有限公司 Chlamydia antigens
US9526778B2 (en) 2009-06-15 2016-12-27 Institut Pasteur De Lille Influenza vaccine, composition, and methods of use
ES2566646T3 (en) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5633152B2 (en) * 2010-02-16 2014-12-03 東ソー株式会社 Adjuvant
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
JP2013533745A (en) 2010-07-06 2013-08-29 ノバルティス アーゲー Immunogenic compositions and methods derived from norovirus
GB2482691B (en) * 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2709658A1 (en) 2011-05-17 2014-03-26 GlaxoSmithKline Biologicals SA Vaccine against streptococcus pneumoniae
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
JP2014531442A (en) 2011-09-14 2014-11-27 ノバルティス アーゲー Escherichia coli vaccine combination
EP2870238A4 (en) 2012-07-05 2016-03-09 Ohio State Innovation Foundation Compositions and methods related to viral vaccines
JP6430949B2 (en) 2012-10-23 2018-11-28 エモリー ユニバーシティ Conjugates, compositions, and related methods of GM-CSF and IL-4
BR112015009229B1 (en) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc COMPOSITION TARGETING THE EXPRESSION OF GENES FOR PLATELETS, USE OF A STEM CELL COMPRISING SUCH COMPOSITION TO TREAT HEMOPHILIA AND IN VITRO OR EX VIVO METHOD TO GENERATE A MODIFIED STEM CELL
JP6306700B2 (en) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ Modified albumin and use thereof
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
JP2017501990A (en) 2013-12-03 2017-01-19 ヴァイロメティックス アーゲー Proline-rich peptide that is protective against S. pneumoniae
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE
EP4226936A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017196979A1 (en) 2016-05-10 2017-11-16 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CN110621676B (en) 2017-05-22 2024-02-09 托帕杜制药公司 Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CA3067587A1 (en) 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation Immunogenic compositions
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2019090238A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CA3117068A1 (en) 2018-11-28 2020-06-04 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
US20230233667A1 (en) 2021-09-08 2023-07-27 Affinivax, Inc. Coronavirus vaccine
KR20230129639A (en) 2022-03-02 2023-09-11 연세대학교 산학협력단 A dual mode of action PDE5 inhibitor/organic nitrate ester in a transdermal dosage form to increase local blood flow

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509188A (en) * 1893-11-21 Barton b
US4629782A (en) * 1984-12-21 1986-12-16 Syntex (U.S.A.) Inc. Crystalline form of N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
CA1337047C (en) * 1988-08-18 1995-09-19 Peter Dodd Cooper Gamma inulin compositions
DK0390435T3 (en) * 1989-03-29 1994-03-21 Takeda Chemical Industries Ltd Mixture containing a compound of the vitamin B group, and preparation thereof
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU5547594A (en) * 1992-11-03 1994-05-24 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1997040163A1 (en) * 1996-04-19 1997-10-30 Metin Colpan Nucleic acid vaccination for parvoviral infections

Also Published As

Publication number Publication date
WO1999027961A1 (en) 1999-06-10
JP2001524533A (en) 2001-12-04
CA2312900A1 (en) 1999-06-10
CN1285753A (en) 2001-02-28
EP1035867A1 (en) 2000-09-20
AU756828B2 (en) 2003-01-23
AU1619999A (en) 1999-06-16
HUP0101139A2 (en) 2001-07-30
NZ504894A (en) 2002-12-20
IL136488A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
IL136488A0 (en) Transdermal delivery of particulate vaccine compositions
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
AP9901673A0 (en) Pharmaceutical compositions having appetite suppresant activity
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
IL123986A0 (en) Antithombotic agents process for their preparation and pharmaceutical compositions comprising them
HUP0002183A3 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
HUP0003761A2 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0101017A3 (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
GB9727053D0 (en) Pharmaceutical compositions
HUP0002510A3 (en) Tetrazole derivatives and pharmaceutical compositions containing them
CY2569B1 (en) Pharmaceutical compositions
EP0941039A4 (en) Transdermal administration of ment
LT99141A (en) Pharmaceutical compositions of tizoxanide and nitazoxanide
GB9710800D0 (en) Pharmaceutical composition and method of preparing it
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
GB9723985D0 (en) Pharmaceutical compositions
IL132516A0 (en) Pharmaceutical compositions of tizoxanide and nitazoxanide
GB9726735D0 (en) Pharmaceutical compositions
EP0987942A4 (en) Pharmaceutical composition and methods for using it
HU9700632D0 (en) Pharmaceutical compositions
AU9588398A (en) Vaccine compositions and methods of enhancing vaccine efficacy
HUP0003159A3 (en) The use of n-monosubstituted-3-oxo-4-aza-5alpha-androst-1-en-17betha-carboxamides for the preparation of pharmaceutical compositions
GB9921495D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees